GENFIT
Announces Publication of
Extra-Financial Performance Report
2022
Lille
(France);
Cambridge, (Massachusetts, United
States); Zurich
(Switzerland); April
27,
2023 - GENFIT (Nasdaq and
Euronext: GNFT), a late-stage biopharmaceutical company
dedicated to improving the lives of patients with rare and severe
liver diseases, today announced the publication of its
Extra-Financial Performance Report 2022.
GENFIT’s
Extra-Financial
Performance
Report in its second
edition
Since 2022, GENFIT has been publishing a
detailed annual report in response to the increasing interest from
institutional investors, individual investors, financial and
Corporate Social Responsibility (CSR) analysts, current employees
and potential candidates, GENFIT’s strategic and industrial
partners and public institutions. The Company is also preparing for
the application of new legal requirements in both Europe and the US
rendering the disclosure of non-financial reporting mandatory.1 The
2022 report is available on the Company website.
GENFIT’s commitment
to CSR
Our commitment is driven, above all, from our
determination to act as a socially responsible company.
As a biopharmaceutical company, this commitment
goes beyond our core activity whose purpose it is to respond to the
societal need of developing innovative, effective and safe
therapeutic solutions for patients suffering from rare and severe
liver diseases with a high unmet medical need. This is aligned with
the third Sustainable Development Goal of the United Nations.
GENFIT believes that there is a correlation
between its long-term financial performance and its extra-financial
performance in that the societal impact of its research and
development programs, as well as the social impact of its activity,
its rigorous governance practices (particularly in relation to the
demands of the relevant health authorities and financial market
regulators) and its low environmental footprint can create
meaningful long-term value for patients, healthcare systems,
employees and shareholders.
Pascal Prigent, Chief Executive Officer
of GENFIT, commented: “GENFIT has always been sensitive to
CSR matters. It makes good ethical sense. Set up in 2021 within the
Board of Directors, the ESG Committee ensures that an annual CSR
roadmap defines a progress trajectory centered around clear
initiatives: implementation of policies, actions and performance
indicators in relation to material issues. Since 2021,
Jean-Christophe Marcoux, Chief Corporate Affairs Officer and member
of the Executive Committee has been overseeing GENFIT’s CSR
program.”
An overview
of GENFIT’s CSR in 2022 and
prospects for 2023
GENFIT’s CSR actions in 2021, its
extra-financial performance progression and its transparent
communication in 2022 were acknowledged by two independent rating
agencies. A bronze medal was awarded by Ethifinance (Gaïa report)
and a “Prime” status label was granted by ISS. In addition, a
social impact investment fund categorized under Article 9 of the
European Sustainable Financial Disclosure Regulation (which
obtained the “Relance” label in France and is a candidate for the
“ISR” label) became shareholder of the company in 2022.
Ever since the Company was created, GENFIT has
maintained regular dialogue with its key internal and external
stakeholders. Such dialogue will be pursued in 2023, through a
formal materiality assessment. Beyond 2023, such dialogue will
enable the Company to regularly reassess its objectives and
progress.
ABOUT GENFIT
GENFIT is a late-stage biopharmaceutical company
dedicated to improving the lives of patients with liver diseases
characterized by high unmet medical needs. GENFIT is a pioneer in
liver disease research and development with a rich history and
strong scientific heritage spanning more than two decades. Thanks
to its expertise in bringing early-stage assets with high potential
to late development and pre-commercialization stages, today GENFIT
boasts a growing and diversified pipeline of innovative therapeutic
and diagnostic solutions.
Its R&D pipeline covers six therapeutic
areas via six programs which explore the potential of
differentiated mechanisms of action, across a variety of
development stages (pre-clinical, Phase 1, Phase 2, Phase 3). These
diseases are acute on-chronic liver failure (ACLF), hepatic
encephalopathy (HE), cholangiocarcinoma (CCA), urea cycle disorder
(UCD), organic acidemia disorder (OAD) and primary biliary
cholangitis (PBC). Beyond therapeutics, GENFIT’s pipeline also
includes a diagnostic franchise focused on NASH and ACLF.
GENFIT has facilities in Lille and Paris
(France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a
publicly traded company listed on the Nasdaq Global Select Market
and on compartment B of Euronext’s regulated market in Paris
(Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s
largest shareholders and holds 8% of the company’s share capital.
www.genfit.com
FORWARD LOOKING STATEMENTS
This press release contains certain
forward-looking statements with respect to GENFIT, including those
within the meaning of the Private Securities Litigation Reform Act
of 1995, in relation to GENFIT’s extra-financial performance and
research and development programs. The use of certain words,
including “consider”, “contemplate”, “think”, “aim”, “expect”,
“understand”, “should”, “aspire”, “estimate”, “believe”, “wish”,
“may”, “could”, “allow”, “seek”, “encourage” or “have confidence”
or (as the case may be) the negative forms of such terms or any
other variant of such terms or other terms similar to them in
meaning is intended to identify forward-looking statements.
Although the Company believes its projections are based on
reasonable expectations and assumptions of the Company’s
management, these forward-looking statements are subject to
numerous known and unknown risks and uncertainties, which could
cause actual results to differ materially from those expressed in,
or implied or projected by, the forward-looking statements. These
risks and uncertainties include, among other things, the
uncertainties inherent in research and development, including in
relation to safety, biomarkers, cost of, progression of, and
results from, its ongoing and planned clinical trials, review and
approvals by regulatory authorities in the United States, Europe
and worldwide, of our drug and diagnostic candidates, exchange rate
fluctuations, potential synergies related to the acquisition of
Versantis, our capacity to integrate its assets, develop its
programs and our continued ability to raise capital to fund our
development, as well as those risks and uncertainties discussed or
identified in the Company’s public filings with the AMF, including
those listed in Chapter 2 “Main Risks and Uncertainties” of the
Company’s 2021 Universal Registration Document filed with the AMF
on April 29, 2022 under n° D.22-0400, which is available on the
Company’s website (www.genfit.com) and on the website of the AMF
(www.amf-france.org) and public filings and reports filed with the
U.S. Securities and Exchange Commission (“SEC”) including the
Company’s 2021 Annual Report on Form 20-F filed with the SEC on
April 29, 2022 and the 2022 Half-Year Business and Financial
Report. In addition, even if the Company’s results, performance,
financial condition and liquidity, and the development of the
industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results
or developments in future periods. These forward-looking statements
speak only as of the date of publication of this document. Other
than as required by applicable law, the Company does not undertake
any obligation to update or revise any forward-looking information
or statements, whether as a result of new information, future
events or otherwise.
CONTACT
GENFIT | Investors
Tel: +33 3 2016 4000 | investors@genfit.com
PRESS RELATIONS | Media
Stephanie Boyer – Press relations | Tel: +333
2016 4000 | stephanie.boyer@genfit.com
GENFIT | 885 Avenue Eugène
Avinée, 59120 Loos - FRANCE | +333 2016 4000 |
www.genfit.com 1
1 The Corporate Sustainability Reporting Directive in Europe
and, in the US The Securities and Exchange Commission published a
proposal in 2022 for non-financial reporting to become mandatory
for listed companies including Foreign Private Issuers
- GENFIT Announces Publication of Extra-Financial Performance
Report 2022
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Nov 2023 à Déc 2023
Genfit (EU:GNFT)
Graphique Historique de l'Action
De Déc 2022 à Déc 2023
